Clinical Trials on Recurrent Melanoma in Ireland

Total 292 results

National Cancer Institute (NCI)

Active, not recruiting

High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Metastatic Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recurrent Mucosal Melanoma | Metastatic Mucosal Melanoma | Non-Cutaneous Melanoma | Metastatic Non-Cutaneous Melanoma | Recurrent Non-Cutaneous...

United States, Canada, Ireland
Cancer Trials Ireland

Completed

A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma (SYS-ACT)

Metastatic Melanoma | Advanced Melanoma

Ireland
Cancer Trials Ireland

Completed

Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma

Melanoma (Skin)

Ireland
Iceland Genomics Corporation
National Cancer Institute (NCI)

Completed

Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members

Melanoma (Skin)

Iceland
National Cancer Institute (NCI)

Completed

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

Stage IV Uveal Melanoma AJCC v7 | Recurrent Uveal Melanoma

United States
National Cancer Institute (NCI)

Completed

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Mucosal Melanoma | Iris Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage IV Uveal Melanoma AJCC v7 | Medium/Large Size Posterior Uveal Melanoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Completed

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IIIA Skin Melanoma

United States, Australia
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Metastatic Melanoma | Recurrent Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)

Terminated

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Acral Lentiginous Malignant Melanoma | Lentigo Maligna Malignant Melanoma | Nodular Malignant Melanoma | Solar Radiation-related Skin Melanoma | Superficial Spreading Malignant Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Melanoma of Unknown Primary | Stage IIIB Cutaneous Melanoma AJCC v7

United States, Canada
St Patrick's Hospital, Ireland

Terminated

Ketamine for Relapse Prevention in Recurrent Depressive Disorder (KINDRED)

Depression | Major Depressive Disorder | Relapse | Recurrent Depressive Disorder

Ireland
Brown University
The Miriam Hospital; Rhode Island Hospital

Active, not recruiting

Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

Melanoma

United States
Hoffmann-La Roche

Completed

A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Malignant Melanoma

United States, Australia
Hoffmann-La Roche

Completed

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

Malignant Melanoma

Italy, United Kingdom, Belgium, Poland, Netherlands, Germany, Austria, Czechia, Ireland, Sweden
NCIC Clinical Trials Group

Completed

Flavopiridol in Treating Patients With Metastatic Malignant Melanoma

Melanoma (Skin)

Canada
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)

Melanoma

Argentina, United States, Australia, Austria, Belgium, Canada, Czechia, Finland, France, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Norway, Poland, Romania, South Africa, Spain, Sweden, Switzerland, Taiwan, United Kingdom
Kiniksa Pharmaceuticals (UK), Ltd.

Completed

A Pilot Study of KPL-914 in Recurrent Pericarditis

Recurrent Pericarditis

United States
European Organisation for Research and Treatment...

Unknown

Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma

Melanoma (Skin)

France, Spain, United Kingdom, Belgium, Australia, Poland, Germany, Netherlands, Slovenia, Italy, Switzerland, Israel, Bulgaria, Croatia, Czech Republic, Estonia, Portugal, Turkey
Brown University
NovoCure Ltd.

Not yet recruiting

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

Metastatic Melanoma | Melanoma Brain Metastasis

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma

Melanoma (Skin)

United States
CancerVax Corporation

Unknown

Vaccine Therapy for Patients With Stage III Melanoma

Malignant Melanoma

United States, France, Australia, Canada, Germany, United Kingdom, Switzerland, Brazil, Ireland, Israel, Italy, Netherlands, New Zealand
CancerVax Corporation

Unknown

Vaccine Therapy for Patients With Stage IV Melanoma

Malignant Melanoma

United States, France, Australia, Canada, Germany, Switzerland, Brazil, Ireland, Israel, Italy, Netherlands, New Zealand, United Kingdom
Bristol-Myers Squibb

Completed

PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma

Melanoma

Italy, Netherlands, Russian Federation, Czechia, Hungary, Ireland, Norway, Spain, Switzerland, Austria, Germany, Denmark, France, Belgium, United Kingdom, United States
Rhode Island Hospital
National Cancer Institute (NCI)

Unknown

Computer-Based Continuing Education for Doctors in Examination and Counseling of Patients on Skin Cancer or Weight Control

Melanoma (Skin) | Non-melanomatous Skin Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

Unresectable Cutaneous Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Mucosal Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Hoffmann-La Roche

Completed

A Study of Vemurafenib in Participants With Metastatic Melanoma

Malignant Melanoma

Canada, Spain, United Kingdom, Hungary, Australia, Austria, Belgium, Ecuador, Estonia, Finland, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Slovenia, Sweden, Turkey, Brazil, India, Germany, Bosnia and Herzegovina and more
Bristol-Myers Squibb

Completed

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma (IMAGE)

Advanced Cutaneous Melanoma

Germany, Poland, Spain, Australia, France, Argentina, Ireland, Israel, Belgium, United States, Switzerland, United Kingdom, Greece, Austria, Canada
Hoffmann-La Roche

Completed

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma (coBRIM)

Malignant Melanoma

United States, Spain, Hungary, Israel, United Kingdom, Australia, Austria, Belgium, Czechia, France, Germany, Italy, Netherlands, Russian Federation, Sweden, Switzerland, Canada, New Zealand, Norway
University College Dublin
Mater Misericordiae University Hospital; Irish Cancer Society

Recruiting

COMpassion FOcused Therapy and Breathing Pattern REtraining After Cancer Recurrence (COMFORT)

Psychological Distress | Cancer Recurrence

Ireland
Bristol-Myers Squibb

Active, not recruiting

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Unresectable or Metastatic Melanoma

United States, France, Poland, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Spain, Sweden, Switzerland, United Kingdom, Russian Federation
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI); NCIC Clinical Trials Group; Children's Oncology... and other collaborators

Active, not recruiting

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Melanoma (Skin)

United States, Canada, Australia, South Africa
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

Locally Advanced Melanoma | Unresectable Melanoma | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma

United States
Bayer
Amgen

Completed

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Melanoma | Cancer

United States
Finch Research and Development LLC.

Terminated

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) (PRISM4)

Recurrent C. Difficile Infection

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Mucosal Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Vical

Completed

A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma

Metastatic Melanoma

United States, Belgium, Brazil, Canada, France, Germany, Israel, Italy, Netherlands, Poland, Russian Federation, Spain, Switzerland, Turkey
National Cancer Institute (NCI)

Recruiting

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC... and other conditions

United States
Cancer Trials Ireland

Completed

Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Melanoma (Skin)

Ireland
Bristol-Myers Squibb

Completed

A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection

Melanoma

Brazil, Chile, United States, Ireland, Italy, Spain, Argentina, Australia, Canada, France, Mexico, New Zealand, Poland, Romania
National Cancer Institute (NCI)

Active, not recruiting

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
GlaxoSmithKline

Completed

A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma (PREDICT)

Melanoma

United States, Spain, Germany, France, Poland, Italy, Ireland, Russian Federation
National Cancer Institute (NCI)

Active, not recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
NRG Oncology

Completed

Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Bristol-Myers Squibb

Completed

Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma (CheckMate 401)

Melanoma

Australia, France, Italy, Belgium, Finland, Austria, Ireland, Sweden, Switzerland, United Kingdom, Germany, Norway
GOG Foundation
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States

Clinical Trials on Recurrent Melanoma in Ireland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations